Incyte's Opzelura EU CHMP and Vega Deal Boost Diversification, But Patent Cliff Overhang Remains

What happened

Incyte received a positive CHMP opinion for Opzelura in Europe and acquired Vega Therapeutics, while Q1 2026 results showed revenue up 21% YoY and ex-Jakafi sales up 63% YoY, reinforcing the diversification narrative. However, the DeepValue Master Report rates INCY a POTENTIAL SELL with a base case of $105, citing a rich ~45x EV/EBITDA multiple and the 2028 Jakafi patent cliff. The bullish news supports the transition story but does not fully de-risk the looming revenue hole, as Opzelura and oncology assets still need to prove they can meaningfully offset Jakafi erosion. With a crowded bullish sentiment and elevated expectations, the stock has limited room for error despite near-term catalysts.

Implication

The CHMP opinion and strong Q1 results improve the probability of a smoother transition, but the stock already prices in this success; look for pullbacks nearer to $90 for a better entry.

Thesis delta

The news strengthens the bull case with tangible progress in Opzelura's European approval and revenue diversification, but the fundamental bear case centered on valuation and the 2028 patent cliff remains intact. The thesis shifts slightly more positive as execution improves, but not enough to change the overall cautious stance given the high multiple and crowded bullish sentiment.